Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Entrada Therapeutics (TRDA) Revenue (2023 - 2025)

Entrada Therapeutics (TRDA) has 3 years of Revenue data on record, last reported at $1.3 million in Q4 2025.

  • For Q4 2025, Revenue fell 96.53% year-over-year to $1.3 million; the TTM value through Dec 2025 reached $25.4 million, down 87.94%, while the annual FY2025 figure was $25.4 million, 87.94% down from the prior year.
  • Revenue reached $1.3 million in Q4 2025 per TRDA's latest filing, down from $1.6 million in the prior quarter.
  • Across five years, Revenue topped out at $94.7 million in Q2 2024 and bottomed at $1.3 million in Q4 2025.
  • Average Revenue over 3 years is $30.4 million, with a median of $22.9 million recorded in 2023.
  • Peak YoY movement for Revenue: skyrocketed 421.16% in 2024, then plummeted 97.94% in 2025.
  • A 3-year view of Revenue shows it stood at $41.8 million in 2023, then dropped by 10.63% to $37.4 million in 2024, then plummeted by 96.53% to $1.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Revenue were $1.3 million in Q4 2025, $1.6 million in Q3 2025, and $2.0 million in Q2 2025.